Home
Adressen
Chronik
Europe
Mariechenmarkt
Visit Gütersloh
Service

Suche nach »Novo Quartet«

Content – Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse, mehr …

Content – Heavy bleeding after giving birth is globally a leading cause of death in new mothers

Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an extension of the Novo Seven (eptacog alfa) label to include treatment of women suffering from severe haemorrhage after giving birth, when medications used to induce uterine contractions and reduce bleeding (uterotonics) are insufficient to stop the bleeding, mehr …

Content – Planta Corps Eigenmarke Acti Novo liefert Gesundheit mit dem Versprechen von Qualität

Schnelle, hochwertige Umsetzung der Produkte »Made in Germany«, mehr …

Content – Novo Nordisk A/S: Share repurchase programme

On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …

Content – Novo Nordisk A/S, Share Repurchase Programme

On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …

Content – Novo Nordisk to Expand R & D Presence in Greater Boston Area

Novo Nordisk just announced plans to expand its research and development (R & D) presence in the greater Boston metro area, creating one of its largest R & D hubs outside of Denmark, mehr …

Content – Novo Nordisk A/S, Share repurchase programme

On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”), mehr …

Content – Novo Nordisk A/S, Share repurchase programme

This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021, mehr …

Content – Novo Nordisk achieves primary objectives of Onwards 1 and 6 trials

Novo Nordisk today announced headline results from the main phases of Onwards 1 (52 weeks) and Onwards 6 (26 weeks) phase 3a trials with once-weekly insulin icodec, mehr …

Content – Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001—a cell therapy designed to restore heart function in people with advanced heart failure

HS 001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs), mehr …

Content – Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines

Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH), mehr …

Content – Novo Nordisk – major shareholder announcement

Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …

Content – Novo Nordisk—major shareholder announcement

Novo Nordisk today announced that the company has been notified by Black Rock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5 percent of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …

Content – Once-weekly insulin icodec demonstrates superior reduction in HbA1c

Mehr …

Content – Novo Nordisk – major shareholder announcement

Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5.05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act, mehr …

Content – Novo Nordisk A/S, Share repurchase programme

The execution of Novo Nordisk A/S’ overall share repurchase programme for 2022 of DKK 24 billion continues, mehr …

Content – Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark

Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities, mehr …

Content – »ApoRisk«: Apotheken Nachrichten vom 18. Dezember 2023 – Update

»Entdecken Sie die dynamische Entwicklung, wegweisende Forschung und die bedeutendsten Herausforderungen, die die Apothekenlandschaft prägen.«, mehr …

Content – Noch Karten für »Musik im Alten Pfarrhaus« am 19. November 2026 in Beckum

»Novo Quartet« spielt Meisterwerke aus 3 Epochen, mehr …

Content – Novo Nordisk files annual report with the SEC

Novo Nordisk A/S has filed its Annual Report 2021 on Form 20-F for the financial year 2021 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2021, mehr …

Content – Forscher entschlüsseln neues Antibiotikum, Rheinische Friedrich Wilhelms Universität Bonn

Immer mehr bakterielle Krankheitserreger entwickeln Resistenzen. Die Gefahr nimmt zu, dass gängige Medikamente nicht mehr gegen Infektionskrankheiten wirken. Forscher der Universität Bonn, des Deutschen Zentrums für Infektionsforschung (DZIF), der Universität Utrecht (Niederlande), der Northeastern University in Boston (USA) und der Firma NovoBiotic Pharmaceuticals in Cambridge (USA) haben nun gemeinsam ein neues Antibiotikum entdeckt und seine Wirkweise aufgeklärt, mehr …

Content – Heidelberger Frühling, Musikfestival und Streichquartettfest 2024, »Brahms!«, 15. März bis 13. April 2024

Vorverkauf startet am 23. Oktober 2023 um 10 Uhr, mehr …

Content – Stefan Kühn: Der Ozempic Hype! Das Diabetes Medikament Ozempic macht als Schlankheitsmittel Furore

Stefan Kühn, Betriebswirt und Ökonom, beleuchtet den Ozempic Hype: »Das Diabetes Medikament Ozempic hat nicht nur einen wichtigen Durchbruch in der Behandlung von Diabetikern erzielt«, mehr …

Content – Das vielfach international ausgezeichnete Marmen Quartet aus London mit Werken von Haydn, Sciarrino und Beethoven

Montag, 4. April 2022, 20 Uhr, Philharmonie Berlin, Kammermusiksaal, mehr …

Content – Initiative Kölner Jazz Haus, Stadtgarten/JAKI, ausgewählte Veranstaltungen im Oktober 2024

Kakuhan ist das Duo Projekt der beiden japanischen Musiker Koshiro Hino und Yuki Nakagawa. Hino ist bekannt für sein Soloprojekt als YPY und als führendes Mitglied der 5 köpfigen Band »goat« (#Japan) sowie für die Leitung der Plattenlabels NAKID und Birdfriend, mehr …

Webcard – Jazz-Club Rheda-Wiedenbrück e. V.

An der Landwehr 22, 33378 Rheda-Wiedenbrück, mehr …